Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-Deoxyuridine (dU) is a nucleoside that commonly occurs as a DNA lesion, arising from cytosine deamination and the incorporation of dUMP by DNA polymerases, processes frequently observed in cancer. The repair of these dU lesions in genomic DNA is primarily mediated by the base excision repair pathway, initiated by Uracil-DNA Glycosylase 2 (UNG2). Modulating pathways involving 2'-deoxyuridine, such as through UNG inhibitors, shows potential for influencing inflammatory responses in tumors. Additionally, 2'-deoxyuridine is identified as a cerebrospinal fluid metabolite, with its levels causally linked to intracranial aneurysms. Derivatives of 2'-deoxyuridine are also being investigated as promising antimicrobial agents, demonstrating inhibitory activity against pathogens like Mycobacterium tuberculosis and Gram-positive bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-Deoxyuridine.